Search Results for: PEPTIDES ANTIBODIES Peptides in Antibody
Articles
Swedish Biomimetics 3000 Ltd Invents Groundbreaking Continuous Peptide Manufacturing Process March 29, 2019
μLOT is an entirely new approach to manufacturing of therapeutic peptides, which promises to completely replace traditional large-scale batch manufacturing....NANOPARTICLE DELIVERY - Ultra-Small Particles Offer Big Hope in Cancer Theranostics February 28, 2019
Kai Ma, PhD, Ulrich Wiesner, and Michelle Bradbury, MD, PhD, believe ultra-small sub-10 nm particles hold unique properties and represent an emerging area of investigation for biomedical applications.
HIGH-RESOLUTION MASS SPECTROMETRY - A Map to Biologics August 27, 2018
William Boomershine, PhD, explains how high-resolution mass spectrometry is a key component to the characterization of novel biologics and biosimilars.
GLOBAL REPORT - 2017 Global Drug Delivery & Formulation Report: Part 4, The Drug Delivery & Formulation Pipeline June 5, 2018
In the final installment of this 4-part series, PharmaCircle in collaboration with Drug Development & Delivery, provides a pipeline review and analysis (centered on drug delivery and formulation products) looking forward and back 5 years for a total of 10 years.
NANOMEDICINES - V-Smart® Nanomedicines: Non-Invasive Targeted Brain Therapeutics for CNS Diseases March 11, 2018
Susan Rosenbaum, JD, and Irwin Hollander, PhD, present a unique and novel solution to this greatest challenge in medicine for brain disease treatment, considered the “Holy Grail of Neuroscience,” with their breakthrough innovation.
Amgen-Backed Immatics Lands $58 Million to Develop T-Cell Receptor-Based Immunotherapies October 5, 2017
Immatics, a leading company in the field of cancer immunotherapy, recently announced the completion of its Series E financing, raising...SPECIAL FEATURE - Analytical Testing: Market Drivers, Growing Demand & Client Needs January 17, 2017
Contributor Cindy H. Dubin spoke with several testing providers to find out what services they offer, trends they identify, and how they have specifically addressed clients’ needs throughout the past year.
PLATFORM TECHNOLOGY - The 3DNA® Platform for Targeted Drug Delivery November 7, 2016
Robert C. Getts, PhD, and Jessica Bowers review how the 3DNA platform is composed entirely of noncoding DNA assembled through the sequential hybridization of single strands of DNA into a network of double-stranded nucleic acid having a controlled architecture, and multiple attachment sites for drug and targeting molecules.
CARBON NANOTUBES - MGMR™ - A Medical-Grade Carbon Nanotube Designed for Medical Applications June 1, 2016
Joseph S. Dillon, PhD, MBA, and Lainie Mulvanny discuss the transformation of CNTs into a unique composition of matter, marking a complete departure from the dirty, tangled micron bundles of CNTs that frustrated medical researchers for years.
PROTEIN CRYSTALS - Reshaping Traditional Biotherapeutic Formulations June 1, 2016
Don Paul Kovarcik, MBA, and William Wittbold, MS, indicate that while protein therapeutics have enjoyed considerable commercial success throughout the past 3 decades, there still remain formulation and delivery challenges.
PROTEIN PHOSPHORYLATION - New Pathways, New Tools: Phosphohistidine Signaling in Mammalian Cells May 3, 2016
Xiaoyi Xu, MS, Chandreyee Das, PhD, and Michael Sturges, PhD, indicate that the phosphorylation of histidine has not been widely studied in mammalian cells, despite its discovery in bovine liver mitochondria, and ask the question, could the phosphorylation of histidine emerge as a therapeutically important pathway in mammals?
DRUG DELIVERY - PLEX(TM) Local Drug Delivery Platform Enables Prolonged, Controlled-Release Medications March 29, 2016
Noam Emanuel, PhD, reviews how PLEX is a unique local drug delivery platform that brings numerous innovative solutions to the market in various fields, such as infections, inflammations, and cancer.
BioCellChallenge Obtains Unprecedented In Vivo Results December 8, 2015
BioCellChallenge SAS recently announced its positive results from in-vivo tests of a therapeutic antibody. The results confirm the efficacy of...EXECUTIVE INTERVIEW - ALTHEA: Giving Biopharmaceutical Companies the Power To Make October 5, 2015
David Enloe, Althea’s President and CEO, discusses his company’s business strategy, why companies choose Althea, trends in the CMO industry, and how the company is growing since the acquisition of Ajinomoto.
MorphoSys & Immatics Biotechnologies Enter Strategic Alliance August 31, 2015
MorphoSys AG and Immatics Biotechnologies GmbH recently announced a strategic alliance to generate novel antibody-based therapeutics against multiple proprietary cancer...Trehalose: A Powerful Excipient in the Formulation Toolbox June 11, 2015
By: Ben Nelson, PhD, and Chris Wilcox (inquiries to: cs@pfanstiehl.com) Trehalose is a non-reducing disaccharide consisting of two glucose...The CDMO Market: Implications of Patheon's IPO June 10, 2015
By: Patricia Van Arnum, DCAT Editorial Director, posted Tue, Jun 09, 2015 04:42 AM Patheon's announcement this week that it plans to...BIOTHERAPEUTICS DEVELOPMENT - The Role of Flow Electroporation in Vaccine Development May 4, 2015
James Brady, PhD, Karen Donato, PhD, and Krista Steger, PhD, indicate that with unmatched quality, flexibility, and scalability, flow electroporation is a universal, cost-effective platform that supports the full range of biotherapeutic and vaccine development activities.
GLOBAL DELIVERY MARKET - Advanced Drug Delivery Systems: mAb, RNAi, & Breaking the Blood-Brain Barrier November 19, 2014
Kevin James, Shalini Dewan, MS, Kim Lawson, and Usha Nagavarapu believe advances in understanding human biology and diseases are opening new and exciting possibilities in the biotechnology industry. R&D spending, along with increasing competition, patent expiries, and new and emerging technologies will continue to shape growth in this market for the foreseeable future.
SPECIAL FEATURE - Outsourcing Formulation Development & Manufacturing: Early-Stage Partnerships Are On The Rise April 2, 2014
Contributor Cindy H. Dubin asked leading CMOs and CDMOs to describe the value-added services they offer with respect to formulation and manufacturing. Solving challenges of insufficient solubility, poor stability, identifying excipient candidates, and particle design topped their list of offerings.
Company Profiles
Pace Analytical Life Sciences
Pace Life Sciences – People Advancing Science HQ: Oakdale, MN 1311 Helmo Avenue North Oakdale, MN 55128 T: (651) 738-2728...Abzena
Abzena - US Headquarters 6325 Lusk Blvd., San Diego, CA 92121 T: (858) 550-4094 Abzena - UK Headquarters Babraham Research...
